Literature DB >> 16545008

Factors associated with poor immunologic response to virologic suppression by highly active antiretroviral therapy in HIV-infected women.

Carlos M Vaamonde1, Donald R Hoover, Kathryn Anastos, Tianren Tan, Qiuhu Shi, Wei Gao, Andrea Kovacs, Mardge Cohen, Jack DeHovitz, Marshall J Glesby.   

Abstract

Virologic response to highly active antiretroviral therapy (HAART) typically results in a substantial rise in CD4 cell counts. We investigated factors associated with poor CD4 response among HIV-infected women followed at 6-monthly intervals in the Women's Interagency HIV Study. Women with nadir CD4 counts < 350 cells/mm3 who achieved at least 6 months of plasma HIV RNA < 400 copies/ml were studied. Demographic, clinical, and treatment factors were compared between immunologic nonresponders, defined as the lower quartile of CD4 count change after two visits with virologic suppression (< 56 cell/mm3; n = 38), and the remaining group of responders (n = 115). Immunologic nonresponders had lower baseline HIV RNA levels and higher CD4 counts, more frequently used HAART 6 months prior to achieving consistent viral suppression, and more commonly had HIV RNA levels > 80 but < 400 copies/mL at both suppressive visits (21 vs. 7.8%, p = 0.024). In multivariate analysis, higher CD4 count and lower HIV RNA level at the last presuppressive visit were associated with immune nonresponse. We conclude that higher baseline CD4 count and lower HIV RNA level were associated with poor immunologic response to HAART in women with virologic suppression for at least 6 months. Persistent low level viremia may also contribute.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16545008      PMCID: PMC3126664          DOI: 10.1089/aid.2006.22.222

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  22 in total

1.  Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study.

Authors:  J P Viard; A Mocroft; A Chiesi; O Kirk; B Røge; G Panos; N Vetter; J N Bruun; M Johnson; J D Lundgren
Journal:  J Infect Dis       Date:  2001-03-26       Impact factor: 5.226

2.  Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response.

Authors:  E Connick; M M Lederman; B L Kotzin; J Spritzler; D R Kuritzkes; M St Clair; A D Sevin; L Fox; M H Chiozzi; J M Leonard; F Rousseau; J D'Arc Roe; A Martinez; H Kessler; A Landay
Journal:  J Infect Dis       Date:  2000-01       Impact factor: 5.226

3.  Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults.

Authors:  J A Bartlett; R DeMasi; J Quinn; C Moxham; F Rousseau
Journal:  AIDS       Date:  2001-07-27       Impact factor: 4.177

4.  Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen.

Authors:  C Piketty; L Weiss; F Thomas; A S Mohamed; L Belec; M D Kazatchkine
Journal:  J Infect Dis       Date:  2001-03-29       Impact factor: 5.226

5.  Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy.

Authors:  S Grabar; V Le Moing; C Goujard; C Leport; M D Kazatchkine; D Costagliola; L Weiss
Journal:  Ann Intern Med       Date:  2000-09-19       Impact factor: 25.391

6.  Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study.

Authors:  G Greub; B Ledergerber; M Battegay; P Grob; L Perrin; H Furrer; P Burgisser; P Erb; K Boggian; J C Piffaretti; B Hirschel; P Janin; P Francioli; M Flepp; A Telenti
Journal:  Lancet       Date:  2000-11-25       Impact factor: 79.321

7.  Predictors of long-term increase in CD4(+) cell counts in human immunodeficiency virus-infected patients receiving a protease inhibitor-containing antiretroviral regimen.

Authors:  Vincent Le Moing; Rodolphe Thiébaut; Geneviève Chêne; Catherine Leport; Valérie Cailleton; Christian Michelet; Hervé Fleury; Serge Herson; François Raffi
Journal:  J Infect Dis       Date:  2002-01-31       Impact factor: 5.226

8.  Multicenter comparison of Roche COBAS AMPLICOR MONITOR version 1.5, Organon Teknika NucliSens QT with Extractor, and Bayer Quantiplex version 3.0 for quantification of human immunodeficiency virus type 1 RNA in plasma.

Authors:  D G Murphy; L Côté; M Fauvel; P René; J Vincelette
Journal:  J Clin Microbiol       Date:  2000-11       Impact factor: 5.948

9.  The relationship between virus load response to highly active antiretroviral therapy and change in CD4 cell counts: A report from the Women's interagency HIV study.

Authors:  J A DeHovitz; A Kovacs; J G Feldman; K Anastos; M Young; M Cohen; S J Gange; S Melnick; R M Greenblatt
Journal:  J Infect Dis       Date:  2000-09-27       Impact factor: 5.226

10.  Low-dose prolonged intermittent interleukin-2 adjuvant therapy: results of a randomized trial among human immunodeficiency virus-positive patients with advanced immune impairment.

Authors:  Giulia Marchetti; Luca Meroni; Stefania Varchetta; Velislava Terzieva; Alessandra Bandera; Daniele Manganaro; Chiara Molteni; Daria Trabattoni; Sabrina Fossati; Mario Clerici; Massimo Galli; Mauro Moroni; Fabio Franzetti; Andrea Gori
Journal:  J Infect Dis       Date:  2002-08-09       Impact factor: 5.226

View more
  3 in total

1.  HIV Drug Resistance Profiles and Clinical Outcomes in Patients with Viremia Maintained at Very Low Levels.

Authors:  Michael R Jordan; Julie Winsett; Aileen Tiro; Vuth Bau; Rony S Berbara; Christopher Rowley; Nobel Bellosillo; Christine Wanke; Eoin P Coakley
Journal:  World J AIDS       Date:  2013-06

2.  Predictors of success with highly active antiretroviral therapy in an antiretroviral-naive urban population.

Authors:  Elisa Zaragoza-Macias; Dominique Cosco; Minh Ly Nguyen; Carlos Del Rio; Jeffrey Lennox
Journal:  AIDS Res Hum Retroviruses       Date:  2010-02       Impact factor: 2.205

3.  Prevalence and Predictors of Virological Failure Among Adults Living with HIV in South Wollo Zone, Northeast Ethiopia: A Retrospective Cohort Study.

Authors:  Teklehaimanot Fentie Wendie; Birhanu Demeke Workneh
Journal:  HIV AIDS (Auckl)       Date:  2020-09-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.